Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Lucid Diagnostics Inc. (NASDAQ:LUCD) is also on this list of popular penny stocks.

TheFly reported on May 15 that Maxim Group reduced its price target on LUCD from $3 to $2 while maintaining a Buy rating following a weaker-than-expected first-quarter revenue report. The company continues to await a Medicare local coverage determination decision, but is actively advancing its commercialization strategy in preparation for potential reimbursement approval, according to the analyst note.

Lucid Diagnostics Inc. (NASDAQ:LUCD) issued its first-quarter 2026 financial results on May 14, alongside a broader business update for the period ended March 31, 2026. The company reported $1.3 million in revenue generated from EsoGuard esophageal DNA testing, based on 3,177 tests processed during the quarter. Operating expenses totaled approximately $13.4 million, including $1.4 million in stock-based compensation, resulting in a GAAP net loss of about $23.6 million attributable to common shareholders. On a non-GAAP basis, adjusted loss was approximately $10.5 million.

Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results

The company also reported cash and equivalents of $27.9 million at quarter’s end, down from $34.7 million at the end of the prior year, while highlighting additional financing activity that improved liquidity and extended projected runway into 2027. Operational updates included expanded clinical and commercial engagement for EsoGuard and EsoCheck, increased participation at major medical conferences, and ongoing adoption efforts supported by emerging clinical guideline developments favoring non-endoscopic testing approaches.

Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage diagnostics company focused on early detection of esophageal precancer in patients with chronic GERD, aiming to help prevent progression to esophageal cancer.

While we acknowledge the risk and potential of LUCD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LUCD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1